Merck's Remigromig Shows Promise, But Safety Concerns Persist

Merck's experimental eye drug remigromig has shown promise in treating diabetic macular edema, but its safety profile is a concern. In the 984-patient BRUNELLO trial, remigromig matched the effectiveness of ranibizumab, the current standard of care, on the primary measure of mean change in best-corrected visual acuity through 52 weeks. However, patients taking remigromig experienced higher rates of certain retinal complications, including proliferative diabetic retinopathy and vitreous hemorrhage.

The company said both doses of remigromig tested, 0.5 mg and 0.8 mg, were generally well-tolerated, but the increased risk of adverse events is a red flag. Analysts are cautioning that more data is needed before making any judgments about remigromig's commercial prospects.

Remigromig targets the Wnt pathway, a cell-signaling network that helps restore the integrity of the blood-retinal barrier. If approved, it would represent the first novel mechanism of action for retinal vascular diseases in over two decades.